Spots Global Cancer Trial Database for histone deacetylase inhibitor
Every month we try and update this database with for histone deacetylase inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours | NCT00697879 | Solid Tumor | CHR-3996 | 18 Years - | Chroma Therapeutics | |
| Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP | NCT01045538 | Gastric Cancer Histone Deacety... | Vorinostat, cap... | 18 Years - | Asan Medical Center | |
| Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma | NCT02213861 | Cutaneous T-Cel... | SHAPE | 18 Years - | TetraLogic Pharmaceuticals | |
| Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma | NCT00865969 | Peripheral T-ce... | Belinostat | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | NCT00666497 | Acute Myeloid L... Myelodysplastic... | Azacitidine MGCD0103 MGCD0103 | 60 Years - | Mirati Therapeutics Inc. | |
| Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL | NCT03564470 | Leukemia Leukemia, Acute Leukemia, Lymph... Leukemia, B-cel... | Chidamide Dasatinib | 14 Years - 55 Years | Nanfang Hospital, Southern Medical University | |
| Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | NCT01087554 | Advanced Cancer | Sirolimus Vorinostat Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | NCT01087554 | Advanced Cancer | Sirolimus Vorinostat Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas | NCT01106872 | Sarcoma Soft Tissue Sar... Locally Advance... Unresectable Sa... Metastatic Sarc... | Bevacizumab, Ge... | 18 Years - 99 Years | University of Iowa | |
| Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration | NCT00878436 | Prostate Cancer Prostatic Neopl... | Panobinostat Bicalutamide | 18 Years - | NYU Langone Health | |
| Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | NCT02756663 | Multiple Myelom... | panobinostat (c... carfilzomib (in... dexamethasone (... | 18 Years - | Novartis | |
| Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma | NCT02213861 | Cutaneous T-Cel... | SHAPE | 18 Years - | TetraLogic Pharmaceuticals | |
| Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration | NCT00878436 | Prostate Cancer Prostatic Neopl... | Panobinostat Bicalutamide | 18 Years - | NYU Langone Health | |
| Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | NCT02909452 | Neoplasms Neoplasms, Glan... Neoplasms by Hi... Bronchial Neopl... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Digestive Syste... Endocrine Gland... Carcinoma, Non-... Lung Diseases Breast Diseases Renal Neoplasm Solid Tumors | Entinostat Pembrolizumab | 18 Years - | Syndax Pharmaceuticals | |
| Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | NCT02756663 | Multiple Myelom... | panobinostat (c... carfilzomib (in... dexamethasone (... | 18 Years - | Novartis | |
| Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL | NCT03553238 | Leukemia, Acute Leukemia, T Cel... Leukemia, Lymph... | Chidamide Dexamethasone vincristine Cyclophosphamid... Idarubicin Pegaspargase Adriamycin Methotrexate 6-Mercaptopurin... Etoposide Cytarabine Bone marrow asp... Intrathecal inj... Radiation thera... NGS allogeneic hema... Flow-MRD FISH Flow immunophen... Karyotyping | 14 Years - 55 Years | Nanfang Hospital, Southern Medical University | |
| Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies | NCT00820508 | Hematological D... Lymphoid Malign... | CHR-2845 | 18 Years - | Chroma Therapeutics | |
| Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL | NCT03553238 | Leukemia, Acute Leukemia, T Cel... Leukemia, Lymph... | Chidamide Dexamethasone vincristine Cyclophosphamid... Idarubicin Pegaspargase Adriamycin Methotrexate 6-Mercaptopurin... Etoposide Cytarabine Bone marrow asp... Intrathecal inj... Radiation thera... NGS allogeneic hema... Flow-MRD FISH Flow immunophen... Karyotyping | 14 Years - 55 Years | Nanfang Hospital, Southern Medical University | |
| Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP | NCT01045538 | Gastric Cancer Histone Deacety... | Vorinostat, cap... | 18 Years - | Asan Medical Center | |
| Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas | NCT01106872 | Sarcoma Soft Tissue Sar... Locally Advance... Unresectable Sa... Metastatic Sarc... | Bevacizumab, Ge... | 18 Years - 99 Years | University of Iowa | |
| Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma | NCT02733380 | Diffuse Large B... | Chidamide Vinorelbine Liposomal Doxor... Dexamethasone Thalidomide | 18 Years - 75 Years | Henan Cancer Hospital | |
| A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma | NCT01486277 | Lymphoma, T-Cel... | Quisinostat, 12... | 18 Years - | Janssen Research & Development, LLC | |
| Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma | NCT02733380 | Diffuse Large B... | Chidamide Vinorelbine Liposomal Doxor... Dexamethasone Thalidomide | 18 Years - 75 Years | Henan Cancer Hospital | |
| Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor. | NCT05411380 | Breast Cancer | Tucidinostat Capecitabine Endocrine Thera... | 18 Years - 75 Years | Sun Yat-sen University | |
| Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours | NCT00697879 | Solid Tumor | CHR-3996 | 18 Years - | Chroma Therapeutics | |
| A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia | NCT00083473 | Leukemia, Lymph... Lymphoma, Small... | Pivanex | 18 Years - | Titan Pharmaceuticals |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
